Sign in to continue:

Tuesday, March 10th, 2026

Sallie Mae Announces $200 Million Accelerated Share Repurchase Under $500 Million Buyback Program in 2026 1

Sallie Mae Announces \$200 Million Accelerated Share Repurchase – Key Details for Investors

Sallie Mae Announces \$200 Million Accelerated Share Repurchase Agreement

Key Points for Investors

  • Accelerated Share Repurchase (ASR) Agreement: Sallie Mae (Nasdaq: SLM) has entered into a \$200 million ASR agreement with Goldman Sachs & Co. LLC. This is a significant development as it represents a fast-tracked commitment to reduce the company’s outstanding shares, which can directly impact earnings per share (EPS) and potentially support the share price.
  • Underwriting Share Repurchase Program: The ASR is part of a broader \$500 million share repurchase program authorized by Sallie Mae’s Board of Directors, effective January 22, 2026. This reflects management’s confidence in the company’s long-term prospects and capital position.
  • Execution Amid Market Dislocation: The repurchase plan was executed promptly following the company’s fourth-quarter earnings announcement, taking advantage of significant market volatility in recent weeks. This demonstrates proactive capital management and an effort to capitalize on potentially depressed share prices.
  • Repurchase Totals: Including this ASR and shares already repurchased this quarter, Sallie Mae’s first-quarter share repurchases and commitments total nearly \$300 million. Management indicated an intention to exhaust most, if not all, of the \$500 million authorization in 2026.
  • Immediate Impact on Share Count: Sallie Mae will prefund the \$200 million ASR on March 10, 2026, and expects to retire a significant portion of the shares soon after execution, providing immediate reduction in the share count and potential EPS accretion.
  • Variable Final Settlement: The final number of shares to be repurchased will depend on the volume-weighted average price of Sallie Mae’s common stock during the ASR term, less a negotiated discount and subject to customary adjustments. At final settlement, the company may receive additional shares or, under certain circumstances, may need to deliver shares or make a cash payment.
  • Timeline: The transactions under the ASR agreement are expected to be completed before the end of the second quarter of 2026.

Potentially Price-Sensitive Information for Shareholders

  • Share Count Reduction and EPS Impact: The immediate retirement of shares through the ASR is likely to have a positive effect on EPS and could provide near-term support to the share price, especially in the context of market dislocation.
  • Continued Repurchase Activity in 2026: Management’s stated intent to use most or all of the \$500 million repurchase authorization during 2026 signals an aggressive approach to capital return, which may be interpreted positively by the market.
  • Uncertainty in Final Share Count and Settlement: The final outcome of the ASR is dependent on market prices and other factors, introducing some uncertainty for investors.
  • Market Conditions: The timing of this announcement—amid significant market dislocation—suggests management sees value in the shares at current levels and is willing to act decisively.

Forward-Looking Statements and Risks

The announcement contains forward-looking statements, including expectations about the completion of the ASR, the total amount of shares repurchased, and the company’s capital allocation strategies. These statements are subject to risks and uncertainties, including those outlined in Sallie Mae’s most recent Annual Report on Form 10-K and other SEC filings. Actual results may differ materially from those implied in the forward-looking statements.

About Sallie Mae

Sallie Mae is a leader in private student lending, providing financing, resources, and products to support access to higher education. The company is not sponsored by or an agency of the United States government.

Contact Information


Disclaimer: This article is for informational purposes only and is not investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review official filings and consult their financial advisors before making investment decisions.


View SLM Corp Historical chart here



TScan Therapeutics Reports Q4 and Full-Year 2025 Results, Advances Hematologic Cancer TCR-T Therapies, and Provides 2026 Business Outlook 123

TScan Therapeutics 2025 Full-Year Financial Results and Business Update: Key Investor Insights TScan Therapeutics Reports 2025 Full-Year Financial Results and Business Update: Detailed Analysis for Investors Key Highlights Positive updated data from the ALLOHA™...

Harrow, Inc. 2025 Annual Report (10-K): Financials, Risk Factors, and Corporate Information

Harrow, Inc. 2025 Annual Report: Key Highlights for Investors Harrow, Inc. 2025 Annual Report: Key Investor Insights and Shareholder Implications Executive Summary Harrow, Inc. (Nasdaq: HROW), a leading pharmaceutical company specializing in branded ophthalmic...

Sturm, Ruger & Company 2025 Annual Report: Business Overview, Risk Factors, Financials, and Corporate Governance

Sturm, Ruger & Company, Inc. 2025 Annual Report: Key Developments and Investor Insights Company Overview and Strategic Positioning Sturm, Ruger & Company, Inc. (“Ruger”), a leading American firearms manufacturer, has released its Annual Report...

   Ad